MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Status:
Completed
Trial end date:
2011-05-26
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy
following a MabThera-containing induction regimen in first line or relapsed patients with
follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface
area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is
1-2 years, and the target sample size is 500+ individuals.